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In our lead finding program, twelve new fluorinated 7-aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-amines were prepared via a practical three-step procedure starting from 
(iso)nicotinic hydrazides. The fluorine substituted aryl fragment was introduced in the last step 
through cyclocondensation of N-(3-pyridyl-1,2,4-triazol-5-yl)guanidines and fluoro / trifluoromethyl 
substituted benzaldehydes. The structures of the compounds were confirmed by 1H and 13C NMR 
spectral data. The tautomeric preferences for the compounds were established using 2D NOESY 
experiments. The antiproliferative activity of the synthesized 1,2,4-triazolo[1,5-a][1,3,5]triazines 
was evaluated against breast, colon and lung cancer cell lines. The highest antiproliferative 
activity in the series was found for 2-(pyridine-3-yl)-7-(4-trifluoromethylphenyl)-6,7-
dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine. The lack of inhibitory activity against bovine 
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1. Introduction 
The unique character of fluorinated molecules is well known in medicinal chemistry [2-8]. Fluorine 
substitution has been extensively practiced in the design of new biologically active compounds, 
including those with potential anticancer properties [8]. A variety of attractive pharmacological 
effects were attributed to the fluorinated mono- and polycyclic 1,3,5-triazines [9]. A bicyclic 
system comprising 1,3,5-triazine and 1,2,4-triazole rings, namely 1,2,4-triazolo[1,5-
a][1,3,5]triazine nucleus, which is 5-aza- bioisoster of purine, has been shown to be a favorable 
scaffold for the design of biologically active compounds [10]. However, data concerning 
anticancer properties of these compounds are limited [11]. Recently, we have developed a new 
method [12] for the synthesis of 5-azapurine derivatives viz. 2-phenyl-6,7-
dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amines via ring closure reaction of N-(3-phenyl-1,2,4-
triazol-5-yl)guanidine using a number of aldehydes and ketones. In continuation of our lead 
finding program in the area of fused 1,3,5-triazines, particularly fluorine substituted derivatives 
[13], we applied herein a similar approach for the preparation of new fluorinated 7-aryl-2-pyridyl-
6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amines (5). We also aimed to investigate 
antiproliferative effect of the compounds towards three cancer cell lines. The monocyclic dihydro-
1,3,5-triazines (e.g. cycloguanil) and some fused dihydro-1,3,5-triazines [14, 15] were reported to 
inhibit the enzyme DHFR, which is a well recognized target in anticancer therapy [16]. Therefore, 
the potential DHFR inhibitory activity of 5 as one of the possible mechanism of the anticancer 
effect was evaluated in the present study.  
We designed the synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazines 5 starting from hydrazides of 
nicotinic and isonicotinic acids (1) which comprised three steps and involved subsequent 
formation of the 1,2,4-triazole and the 1,3,5-triazine rings (Scheme 1). In order to generate a 
library of fluorinated 1,2,4-triazolo[1,5-a][1,3,5]triazine derivatives for biological screening, fluorine 
/ trifluoromethyl substituted benzaldehydes were used in the step of 1,3,5-triazine ring closure.  
 
2. Results and discussion  
2.1. Chemistry  
The reaction of cyanoguanidine with hydrazides of nicotinic and isonicotinic acids (1) in the 
presence of hydrochloric acid provided N-(iso)nicotinamidobiguanides (2) (Scheme 1). The 
biguanides 2 were further cyclized under alkaline conditions to afford N-(3-pyridyl-1,2,4-triazol-5-
yl)guanidine (3).  
Heating of guanidines 3 with fluorinated benzaldehydes in ethanol in the presence of piperidine 
gave 7-aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amines (5) (Scheme 1). The 
characteristic signal at 64.2-64.8 ppm for the compounds with ortho-substituted phenyl group and 
67.6-67.8 ppm for the compounds with meta- and para-substituted phenyl group was found in 13C 
NMR spectra. This indication of the presence of sp3-hybridized carbon atom in the structure 
supported the triazine ring closure and ruled out the structure of conceivable Schiff base-like 
intermediates 4. The heterocyclization was found to proceed regioselectively resulting in the 
formation of fused triazolotriazine system 5 with the [1,5-a] ring junction, exclusively. The 
theoretically possible regioisomeric 1,2,4-triazolo[4,3-a][1,3,5]triazines 6 were not isolated from 
the reaction mixture. The 2D NOESY experiments were used to differentiate between 
triazolotriazine structures 5 and 6. The pyridine ring protons gave no cross-peaks neither with 
proton at sp3-hybridized carbon nor with protons of fluorinated aryl group. The results are in 
agreement with those obtained in our previous studies [12] for structurally related compounds.  
The annular tautomerism, possible for 5, might result in the existence of four different forms viz. 
6,7- (A), 1,7- (B), 4,7- (C), and 3,7-dihydro- (D) tautomers (Scheme 2). However, form A was 
found to be predominant in Me2SO solution as indicated by the NMR data. The coupling of proton 
at sp3-hybridized carbon (H-7) and proton of endocyclic NH in 1H NMR spectra was observed for 
several compounds (J = 0-1.1 Hz). Despite J value was small and not always detectable, cross-
peaks between these signals in 2D NOESY experiments clearly indicated that the NH proton was 
located in the vicinity of sp3-hybridized carbon.  
 
2.2. Biological activity 
The antiproliferative and DHFR inhibitory activities were evaluated for the prepared fluorinated 7-
aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amines (5a-l). For both the 
antiproliferative and DHFR inhibition bioassays the compounds were dissolved in Me2SO. In 
order to ensure that the solvent per se had no effect on the cell growth and enzymatic activity, 
negative control tests were performed using Me2SO at the same concentrations. The 
antiproliferative activity was performed using MTT assay [17]. The following cancer cell lines were 
used for the screening: breast cancer MDA-MB-231, colon cancer HT-29 and lung cancer A549. 
The DHFR inhibition bioassay was carried out using bovine DHFR (Fluka Chemie) according to 
the previously described method [13]. The concentrations of the compounds for the biological 
tests were varied according to their solubility in the media. The effect of the compounds was 
expressed as percentage of cell growth inhibition (antiproliferative assay) and percentage of the 
enzymatic activity inhibition (DHFR assay). IC50 value was determined for the most active 
compound.  
The results of the antiproliferative tests of compounds 5 are shown in Table 1. In general, the 
lung cancer cells were more resistant to the treatment with 1,2,4-triazolo[1,5-a][1,3,5]triazines 5, 
while the colon cancer cells were more susceptible. However, the most active compound, namely 
2-(pyridine-3-yl)-7-(4-trifluoromethylphenyl)-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine 
(5f) was more effective against breast cancer sell line MDA-MB-231 (IC50 = 28 μM). The position 
of fluoro / trifluoromethyl group seemed to play more important role in the anticancer effect of the 
compounds than position of nitrogen in the pyridine ring. Thus, the active compounds were 
almost equally distributed within 3- and 4-pyridyl substituted groups (5a-f and 5g-l). At the same 
time, the pairs of the compounds with pronounced anticancer effect were identified, those 
included 5f and 5l (R = 4-CF3) as well as 5b and 5h (R = 3-F). The pairs showed similar activity 
and selectivity towards the cell lines used for the evaluation.  
None of 1,2,4-triazolo[1,5-a][1,3,5]triazines 5 demonstrated significant inhibition of the bovine 
DHFR activity in the screening (Table 2). Therefore, the anticancer effect of the compounds 
appeared to be realized via mechanisms other than DHFR inhibition.  
 
3. Conclusions 
Twelve new fluorinated 7-aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amines (5) 
were prepared using simple and effective three-step procedure. The biological evaluation showed 
that compounds 5 possessed the anticancer properties not associated with DHFR inhibition. The 
most active anticancer agents identified in this study was 2-(pyridine-3-yl)-7-(4-
trifluoromethylphenyl)-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (5f). Therefore it may 
be used as a lead for further development.  
 
4. Experimental  
Melting points (uncorrected) were determined on a Gallenkamp melting point apparatus. 
Analytical TLC were carried out on aluminum plates coated with Silica gel 60 F254 (Merck) with 
detection by UV light. 1H and 13C NMR spectra were recorded on a Bruker DPX-300 
spectrometer, using Me2SO-d6 as a solvent and TMS as an internal reference.  
 
4.1. N-Nicotinamidobiguanide hydrochloride (2a)  
To the solution of nicotinic hydrazide (1a, 6.80 g, 50 mmol) in ethanol (50 mL), hydrochloric acid 
(37%, 5 ml, 50 mmol) and cyanoguanidine (4.62 g, 55 mmol) were added. The reaction mixture 
was heated under reflux with stirring for 8 h. After cooling, the product was filtered, washed with 
cold ethanol and dried. Yield 80%; mp 176-177 °C (aq. EtOH) [lit. [18] mp 178-189 °C]. 1H NMR 
(300 MHz, DMSO-d6): δ 7.58 (7H, br s, NH-C(=NH)NH-C(=NH)NH2 HCl), 7.74 (1H, dd, 3J = 7.5 
Hz, 3J = 4.9 Hz, H-5), 8.52 (1H, d, 3J = 7.5 Hz, H-4), 8.86 (1H, d, 3J = 4.9 Hz, H-6), 9.21 (1H, s, H-
2), 11.16 (1H, s, CONH). 13C NMR (75 MHz, DMSO-d6): δ 124.3 (C-5), 128.8 (C-3), 138.0 (C-4), 
146.8 (C-6), 150.0 (C-2), 157.3, 158.5 (NH-C(=NH)NH-C(=NH)NH2), 163.6 (C=O).  
 
4.2. N-Isonicotinamidobiguanide dihydrochloride (2b)  
To the solution of isonicotinic hydrazide (1b, 6.80 g, 50 mmol) in methanol (70 mL), hydrochloric 
acid (37%, 10 mL, 100 mmol) and cyanoguanidine (4.62 g, 55 mmol) were added. The reaction 
mixture was heated under reflux with stirring for 8 h. After cooling, the product was filtered, 
washed with cold ethanol and dried. Yield 82%, mp 198 °C (aq EtOH) [lit. [19] mp 200 °C]. 
1H NMR (300 MHz, DMSO-d6): δ 7.59 (8H, br s, NH-C(=NH)NH-C(=NH)NH2 2HCl), 8.04 (2H, d, 
3J = 5.9 Hz, 4J = 1.5 Hz, H-3 and H-5), 8.85 (2H, dd, 3J = 5.9 Hz, 4J = 1.5 Hz, H-2 and H-6), 11.18 
(1H, s, CONH). 13C NMR (75 MHz, DMSO-d6): δ 122.6 (C-3 and C-5), 141.4 (C-4), 148.0 (C-2 
and C-6), 156.7, 158.4 (NH-C(=NH)NH-C(=NH)NH2), 163.3 (C=O).  
 
4.3. General method for the syntheses of N-(3-Pyridyl-1H-1,2,4-triazol-5-yl)guanidine (3a,b) 
N-(Iso)nicotinamidobiguanide (di)hydrochloride (2, 20 mmol) was heated at 80 °C in 10% 
aqueous sodium hydroxide solution (10 mL) for 4-6 h. After cooling, the product was filtered, 
washed with cold water and dried.  
 
4.3.1. N-[3-(Pyridin-3-yl)-1H-1,2,4-triazol-5-yl]guanidine (3a)  
Yield 86%, mp 269 °C (EtOH) [lit. [18] mp 275-276 °C]; TLC (silica gel, EtOH): Rf 0.15. 1H NMR 
(300 MHz, DMSO-d6): δ 6.70 (4H, br s, NH-C(=NH)NH2), 7.45 (1H, dd, 3J = 7.9 Hz, 3J = 4.5 Hz, 
H-5), 8.28 (1H, dt, 3J = 7.9 Hz, 4J = 1.7 Hz, H-4), 8.56 (1H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-6), 9.16 
(1H, d, 4J = 1.9 Hz, H-2), 12.58 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): δ 123.5 (C-5’), 
127.9 (C-3’), 132.4 (C-4’), 146.5 (C-6’), 149.0 (C-2’), 154.9 (C-3), 157.9 (NH-C(=NH)NH2), 160.8 
(C-5).  
 
4.3.2. N-[3-(Pyridin-4-yl)-1H-1,2,4-triazol-5-yl]guanidine (3b)  
Yield 92%, mp 289-290 °C (EtOH) [lit. [18] mp 292 °C]; TLC (silica gel, EtOH): Rf 0.20. 1H NMR 
(300 MHz, DMSO-d6): δ 6.73 (4H, br s, NH-C(=NH)NH2), 7.88 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, 
H-3’ and H-5’), 8.62 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-2’ and H-6’), 12.70 (1H, br s, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 119.5 (C-3’ and C-5’), 139.2 (C-1’), 149.9 (C-2’ and C-6’), 155.2 (C-
3), 157.9 (NH-C(=NH)NH2), 160.9 (C-5).  
 
4.4. General method for the syntheses of 7-aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-amine (5a-l)  
The solution of N-(3-pyridyl-1,2,4-triazol-5-yl)guanidine (3, 0.50 g, 2.5 mmol), fluorine / 
trifluoromethyl substituted benzaldehyde (2.5 mmol) and piperidine (0.10 mL, 1.0 mmol) in 
ethanol (7-10 mL) was heated under reflux for 5-18 h. After cooling, the product was filtered, 




Yield 85%; mp 280 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.45. 1H NMR (300 MHz, Me2SO-
d6): δ 6.48 (2H, s, NH2), 6.97 (1H, s, H-7), 7.22-7.34 (3H, m, H-3’’, H-5’’ and H-6’’), 7.42 (1H, dd, 
3J = 7.7 Hz, 3J = 4.3 Hz, H-5’), 7.44-7.52 (1H, m, H-4’’), 8.03 (1H, s, NH), 8.17 (1H, dt, 3J = 7.9 
Hz, 4J = 1.9 Hz, H-4’), 8.55 (1H, dd, 3J = 4.7 Hz, 4J = 1.7 Hz, H-6’), 9.02 (1H, d, 4J = 1.5 Hz, H-2’). 
13C NMR (75 MHz, Me2SO-d6): δ 64.2 (d, 3JC-F = 3.5 Hz, C-7), 116.0 (d, 2JC-F = 20.6 Hz, C-3’’), 
123.4 (C-5’), 124.8 (d, 4JC-F = 3.5 Hz, C-5’’), 127.0 (d, 2JC-F = 11.8 Hz, C-1’’), 127.4 (C-3’), 128.4 
(d, 3JC-F = 3.5 Hz, C-6’’), 131.4 (d, 3JC-F = 8.2 Hz, C-4’’), 132.6 (C-4’), 146.5 (C-6’), 149.5 (C-2’), 
155.6, 156.7, 157.3 (C-2, C-3a and C-5), 159.7 (d, 1JC-F = 248.1 Hz, C-2’’). Anal. Calcd for 




Yield 87%; mp 288 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.43. 1H NMR (300 MHz, Me2SO-
d6): δ 6.60 (2H, s, NH2), 6.81 (1H, s, H-7), 7.16-7.31 (3H, m, H-2’’, H-4’’ and H-6’’), 7.44 (1H, dd, 
3J = 7.9 Hz, 3J = 4.9 Hz, H-5’), 7.51 (1H, td, 3J = 7.6 Hz, 4JH-F = 6.4 Hz, H-5’’), 8.12 (1H, s, NH), 
8.20 (1H, dt, 3J = 7.9 Hz, 4J = 1.9 Hz, H-4’), 8.57 (1H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-6’), 9.06 (1H, 
d, 4J = 1.5 Hz, H-2’). 13C NMR (75 MHz, Me2SO-d6): δ 67.6 (d, 4JC-F = 1.8 Hz, C-7), 113.1 (d, 2JC-F 
= 21.8 Hz, C-2’’), 116.0 (d, 2JC-F = 21.2 Hz, C-4’’ ), 122.3 (d, 4JC-F = 2.9 Hz, C-6’’), 123.6 (C-5’), 
127.4 (C-3’), 131.1 (d, 3JC-F = 8.2 Hz, C-5’’), 132.7 (C-4’), 142.9 (d, 3JC-F = 6.5 Hz, C-1’’), 146.6 
(C-6’), 149.5 (C-2’), 155.6, 156.6, 157.4 (C-2, C-3a and C-5), 162.1 (d, 1JC-F = 245.2 Hz, C-3’’). 




Yield 91%; mp 281 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.40. 1H NMR (300 MHz, Me2SO-
d6): δ 6.55 (2H, s, NH2), 6.79 (1H, d, 3J = 1.1 Hz, H-7), 7.28 (2H, dd, 3J = 8.7 Hz, 3JH-F = 9.0 Hz, 
H-3’’ and H-5’’), 7.39-7.48 (3H, m, H-5’, H-2’’ and H-6’’), 8.03 (1H, d, 3J = 1.1 Hz, NH), 8.18 (1H, 
dt, 3J = 7.9 Hz, 4J = 1.9 Hz, H-4’), 8.56 (1H, dd, 3J = 4.9 Hz, 4J = 1.5 Hz, H-6’), 9.05 (1H, d, 4J = 
1.9 Hz, H-2’). 13C NMR (75 MHz, Me2SO-d6): δ 67.7 (C-7), 115.7 (d, 2JC-F = 21.8 Hz, C-3’’ and C-
5’’), 123.6 (C-5’), 127.4 (C-3’), 128.6 (d, 3JC-F = 8.2 Hz, C-2’’ and C-6’’), 132.6 (C-4’), 136.5 (d, 4JC-
F = 2.9 Hz, C-1’’), 146.6 (C-6’), 149.5 (C-2’), 155.6, 156.6, 157.3 (C-2, C-3a and C-5), 162.4 (d, 
1JC-F = 245.2 Hz, C-4’’). Anal. Calcd for C15H12FN7: C, 58.25; H, 3.91; N, 31.70. Found: C, 58.03; 




Yield 87%; mp 285 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.49. 1H NMR (300 MHz, Me2SO-
d6): δ 6.50 (2H, s, NH2), 6.99 (1H, s, H-7), 7.34 (1H, d, 3J = 7.9 Hz, H-6’’), 7.41 (1H, dd, 3J = 7.9 
Hz, 3J = 4.7 Hz, H-5’), 7.64 (1H, t, 3J = 7.5 Hz, H-5’’), 7.76 (1H, t, 3J = 7.5 Hz, H-4’’), 7.85 (1H, d, 
3J = 7.5 Hz, H-3’’), 8.00 (1H, s, NH), 8.16 (1H, dt, 3J = 7.9 Hz, 4J = 1.9 Hz, H-4’), 8.55 (1H, dd, 3J 
= 4.9 Hz, 4J = 1.5 Hz, H-6’), 9.02 (1H, d, 4J = 1.5 Hz, H-2’). 13C NMR (75 MHz, Me2SO-d6): δ 64.7 
(q, 4JC-F = 2.9 Hz, C-7), 123.6 (C-5’), 127.2 (C-3’), 123.9 (q, 1JC-F = 274.4 Hz, CF3), 125.8 (q, 3JC-F 
= 5.7 Hz, C-3’’), 126.0 (q, 2JC-F = 30.6 Hz, C-2’’), 128.4 (C-6’’), 129.9 (C-4’’), 132.7 (C-4’), 133.8 
(C-5’’), 138.6 (q, 3JC-F = 1.2 Hz, C-1’’), 146.6 (C-6’), 149.6 (C-2’), 155.3, 157.1, 157.7 (C-2, C-3a 




amine (5e)  
Yield 86%; mp 260 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.45. 1H NMR (300 MHz, Me2SO-
d6): δ 6.63 (2H, s, NH2), 6.92 (1H, s, H-7), 7.43 (1H, dd, 3J = 7.7 Hz, 3J = 4.7, H-5’), 7.63 (1H, d, 
3J = 7.5 Hz, H-4’’), 7.71 (1H, t, 3J = 7.9 Hz, C-5’’), 7.80 (1H, s, H-2’’), 7.81 (1H, d, 3J = 7.9 Hz, H-
6’’), 8.15 (1H, s, NH), 8.19 (1H, dt, 3J = 7.9 Hz, 4J = 1.9 Hz, H-4’), 8.57 (1H, dd, 3J = 4.7 Hz, 4J = 
1.7 Hz, H-6’), 9.06 (1H, d, 4J = 1.9 Hz, H-2’). 13C NMR (75 MHz, Me2SO-d6): δ 67.7 (C-7), 123.0 
(q, 3JC-F = 3.7 Hz, H-4’’), 123.6 (C-5’), 123.9 (q, 1JC-F = 272.4 Hz, CF3), 126.0 (q, 3JC-F = 3.3 Hz, C-
2’’), 127.4 (C-3’), 129.6 (q, 2JC-F = 31.9 Hz, C-3’’), 130.2 (C-6’’), 130.4 (q, 4JC-F = 1.2 Hz, H-5’’), 
132.7 (C-4’), 141.5 (C-1’’), 146.6 (C-6’), 149.6 (C-2’), 155.6, 156.7, 157.5 (C-2, C-3a and C-5). 




Yield 93%; mp 274 °C (EtOH); TLC (silica gel, EtOH): Rf 0.41. 1H NMR (300 MHz, Me2SO-d6): δ 
6.58 (2H, s, NH2), 6.88 (1H, s, H-7), 7.42 (1H, dd, 3J = 7.9 Hz, 3J = 4.5 Hz, H-5’), 7.58 (2H, d, 3J = 
8.3 Hz, H-2’’ and H-6’’), 7.84 (2H, d, 3J = 8.3 Hz, H-3’’ and H-5’’), 8.09 (1H, s, NH), 8.17 (1H, dt, 
3J = 8.3 Hz, 4J = 1.8 Hz, H-4’), 8.55 (1H, dd, 3J = 4.9, 4J = 1.5 Hz, H-6’), 9.03 (1H, d, 4J = 1.9 Hz, 
H-2’). 13C NMR (75 MHz, Me2SO-d6): δ 67.7 (C-7), 123.6 (C-5’), 123.9 (q, 1JC-F = 272.2 Hz, CF3), 
125.8 (q, 3JC-F = 3.7 Hz, C-3’’ and C-5’’), 127.2 (C-2’’ and C-6’’), 127.3 (C-3’), 129.5 (q, 2JC-F = 
31.8 Hz, C-4’’), 132.7 (C-4’), 144.4 (C-1’’), 146.5 (C-6’), 149.5 (C-2’), 155.5, 156.7, 157.5 (C-2, C-





Yield 85%; mp 285 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.46. 1H NMR (300 MHz, Me2SO-
d6): δ 6.57 (2H, s, NH2), 7.01 (1H, s, H-7), 7.22-7.39 (3H, m, H-3’’, H-5’’ and H-6’’), 7.44-7.52 (1H, 
m, H-4’’), 7.78 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-3’ and H-5’), 8.11 (1H, s, NH), 8.60 (2H, dd, 3J 
= 4.5 Hz, 4J = 1.5 Hz, H-2’ and H-6’). 13C NMR (75 MHz, Me2SO-d6): δ 64.4 (d, 3JC-F = 2.9 Hz, C-
7), 116.1 (d, 2JC-F = 20.6 Hz, C-3’’), 119.6 (C-3’ and C-5’), 124.8 (d, 4JC-F = 3.5 Hz, C-5’’), 126.9 
(d, 2JC-F = 11.8 Hz, C-1’’), 128.5 (d, 3JC-F = 3.5 Hz, C-6’’), 131.5 (d, 3JC-F = 8.2 Hz, C-4’’), 138.6 (C-
1’), 150.0 (C-2’ and C-6’), 155.6, 156.8, 157.5 (C-2, C-3a and C-5), 159.7 (d, 1JC-F = 248.7 Hz, C-




Yield 87%; mp 288 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.44. 1H NMR (300 MHz, Me2SO-
d6): δ 6.61 (2H, s, NH2), 6.81 (1H, d, 3J = 1.1 Hz, H-7), 7.16-7.31 (3H, m, H-2’’, H-4’’ and H-6’’), 
7.51 (1H, td, 3J = 8.1 Hz, 4JH-F = 6.0 Hz, H-5’’), 7.79 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-3’ and H-
5’), 8.11 (1H, d, 3J = 1.1 Hz, NH), 8.60 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-2’ and H-6’). 13C NMR 
(75 MHz, Me2SO-d6): δ 67.6 (d, 4JC-F = 1.2 Hz, C-7), 113.2 (d, 2JC-F = 22.3 Hz, C-2’’), 116.0 (d, 
2JC-F = 20.6 Hz, C-4’’), 119.6 (C-3’ and C-5’), 122.3 (d, 4JC-F = 2.4 Hz, C-6’’), 131.1 (d, 3JC-F = 7.6 
Hz, C-5’’), 138.6 (C-1’), 142.7 (d, 3JC-F = 6.5 Hz, C-1’’), 150.0 (C-2’ and C-6’), 155.6, 156.7, 157.5 
(C-2, C-3a and C-5), 162.1 (d, 1JC-F = 245.2 Hz, C-3’’). Anal. Calcd for C15H12FN7: C, 58.25; H, 
3.91; N, 31.70. Found: C, 58.14; H, 4.02; N, 31.43.  
 
4.4.9. 7-(4-Fluorophenyl)-2-(pyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (5i) 
Yield 92%; mp 288-289 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.46. 1H NMR (300 MHz, 
Me2SO-d6): δ 6.54 (2H, s, NH2), 6.78 (1H, s, H-7), 7.28 (2H, dd, 3J = 8.7 Hz, 3JH-F = 9.0 Hz, H-3’’ 
and H-5’’), 7.42 (2H, dd, 3J = 8.7 Hz, 4JH-F = 5.7 Hz, H-2’’ and H-6’’), 7.77 (2H, dd, 3J = 4.5 Hz, 4J 
= 1.5 Hz, H-3’ and H-5’), 8.02 (1H, s, NH), 8.59 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-2’ and H-6’). 
13C NMR (75 MHz, Me2SO-d6): δ 67.8 (C-7), 115.7 (d, 2JC-F = 21.8 Hz, C-3’’ and C-5’’), 119.6 (C-
3’ and C-5’), 128.6 (d, 3JC-F = 8.8 Hz, C-2’’ and C-6’’), 136.4 (d, 4JC-F = 2.9 Hz, C-1’’), 138.7 (C-1’), 
150.0 (C-2’ and C-6’), 155.7, 156.7, 157.5 (C-2, C-3a and C-5), 162.4 (d, 1JC-F = 245.2 Hz, C-4’’). 




Yield 86%; mp 278 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.51. 1H NMR (300 MHz, Me2SO-
d6): δ 6.52 (2H, s, NH2), 7.01 (1H, s, H-7), 7.36 (1H, d, 3J = 7.5 Hz, H-6’’), 7.64 (1H, t, 3J = 7.5 Hz, 
H-5’’), 7.76 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-3’ and H-5’), 7.77 (1H, t, 3J = 7.5 Hz, H-4’’), 7.85 
(1H, d, 3J = 7.5 Hz, H-3’’), 8.03 (1H, s, NH), 8.58 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-2’ and H-6’).  
13C NMR (75 MHz, Me2SO-d6): δ 64.8 (q, 4JC-F = 2.9 Hz, C-7), 119.7 (C-3’ and C-5’), 123.9 (q, 1JC-
F = 274.6 Hz, CF3), 125.8 (q, 3JC-F = 5.3 Hz, C-3’’), 126.0 (q, 2JC-F = 30.6 Hz, C-2’’), 128.5 (C-6’’), 
129.9 (C-4’’), 133.8 (C-5’’), 138.5 (C-1’ and C-1’’), 150.0 (C-2’ and C-6’), 155.4, 157.2, 157.8 (C-
2, C-3a and C-5). Anal. Calcd for C16H12F3N7: C, 53.48; H, 3.37; N, 27.29. Found: C, 53.60; H, 
3.42; N, 26.02.  
 
4.4.11. 2-(Pyridin-4-yl)-7-(3-trifluoromethylphenyl)-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
amine (5k)  
Yield 90%; mp 258 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.46. 1H NMR (300 MHz, Me2SO-
d6): δ 6.62 (2H, s, NH2), 6.92 (1H, s, H-7), 7.62 (1H, d, 3J = 7.9 Hz, H-6’’), 7.70 (1H, t, 3J = 7.7 Hz, 
H-5’’), 7.77 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-3’ and H-5’), 7.79 (1H, s, H-2’’), 7.81 (1H, d, 3J = 
7.5 Hz, H-4’’), 8.13 (1H, s, NH), 8.60 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-2’ and H-6’). 13C NMR 
(75 MHz, Me2SO-d6): δ 67.7 (C-7), 119.6 (C-3’ and C-5’), 123.1 (q, 3JC-F = 3.9 Hz, C-2’’), 123.9 (q, 
1JC-F = 272.2 Hz, CF3), 126.0 (q, 3JC-F = 3.5 Hz, C-4’’), 129.4 (q, 2JC-F = 31.8 Hz, C-3’’), 130.2 (C-
6’’), 130.4 (q, 4JC-F = 1.2 Hz, C-5’’), 138.6 (C-1’), 141.3 (C-1’’), 150.0 (C-2’ and C-6’), 155.6, 
156.8, 157.7 (C-2, C-3a and C-5). Anal. Calcd for C16H12F3N7: C, 53.48; H, 3.37; N, 27.29. Found: 
C, 53.36; H, 3.32; N, 27.40.  
 
4.4.12. 2-(Pyridin-4-yl)-7-(4-trifluoromethylphenyl)-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
amine (5l)  
Yield 88%; mp 297-298 °C (EtOH - DMF); TLC (silica gel, EtOH): Rf 0.46. 1H NMR (300 MHz, 
Me2SO-d6): δ 6.61 (2H, s, NH2), 6.90 (1H, d, 3J = 1.1 Hz, H-7), 7.59 (2H, d, 3J = 8.3 Hz, H-2’’ and 
H-6’’), 7.77 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-3’ and H-5’), 7.84 (2H, d, 3J = 8.3 Hz, H-3’’ and H-
5’’), 8.11 (1H, d, 3J = 1.1 Hz, NH), 8.59 (2H, dd, 3J = 4.5 Hz, 4J = 1.5 Hz, H-2’ and H-6’). 13C NMR 
(75 MHz, Me2SO-d6): δ 67.8 (C-7), 119.7 (C-3’ and C-5’), 123.9 (q, 1JC-F = 272.8 Hz, CF3), 125.9 
(q, 3JC-F = 3.5 Hz, C-3’’ and C-5’’), 127.3 (C-2’’ and C-6’’), 129.7 (q, 2JC-F = 31.8 Hz, C-4’’), 138.6 
(C-1’), 144.3 (C-1’’), 150.0 (C-2’ and C-6’), 155.7, 156.8, 157.7 (C-2, C-3a and C-5). Anal. Calcd 
for C16H12F3N7: C, 53.48; H, 3.37; N, 27.29. Found: C, 53.23; H, 3.28; N, 27.52.  
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Table 1. Antiproliferative activity of the fluorinated 7-aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-amines (5a-l)  
Compound Py RF Concentration, 
µM 
Cell growth inhibition, %* 
MDA-MB-231 HT29 A549 
5a 3-Py 2-F 62.5 12±5.9 17±9.4 13±6.7 
   125 17±3.8 29±9.3 26±9.6 
5b 3-Py 3-F 62.5 21±6.3 28±9.7 12±7.2 
5c 3-Py 4-F 62.5 8±7.9 13±9.3 2±5.5 
   125 18±6.1 29±7.0 6±6.7 
5d 3-Py 2-CF3 62.5 3±7.2 1±13.0 1±9.6 
   125 12±6.5 7±10.0 6±6.7 
5e 3-Py 3-CF3 62.5 17±8.0 29±6.1 12±8.3 
   125 41±7.7 51±5.1 20±5.5 
5f 3-Py 4-CF3 62.5 65±12.5 40±16.1 32±11.1 
   125 75±6.4 48±17.2 41±9.3 
5g 4-Py 2-F 62.5 3±10.4 16±6.4 -3±13.7 
   125 11±9.8 25±7.4 -1±10.2 
5h 4-Py 3-F 62.5 19±18.8 25±16.1 7±16.4 
   125 44±12.7 54±16.9 30±12.5 
5i 4-Py 4-F 62.5 21±5.1 13±6.4 -2±5.5 
   125 30±6.2 34±5.2 10±6.3 
5j 4-Py 2-CF3 50 22±6.4 14±6.9 14±6.5 
5k 4-Py 3-CF3 62.5 2±6.7 14±11.7 0±9.0 
   125 19±5.1 42±15.5 15±8.8 
5l 4-Py 4-CF3 62.5 30±12.5 20±17.1 27±15.1 
   125 44±13.3 29±11.1 44±10.2 
* ± - SD, n = 5-6  
 
Table 2 
Bovine DHFR inhibitory activity of the fluorinated 7-aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-amines (5a-l)  
Compound Py RF Concentration, µM Inhibition, % 
5a 3-Py 2-F 500 14 
5b 3-Py 3-F 500 12 
5c 3-Py 4-F 500 na 
5d 3-Py 2-CF3 500 32 
5e 3-Py 3-CF3 250 na 
5f 3-Py 4-CF3 100 na 
5g 4-Py 2-F 500 11 
5h 4-Py 3-F 500 20 
5i 4-Py 4-F 500 9 
5j 4-Py 2-CF3 250 22 
5k 4-Py 3-CF3 500 7 
5l 4-Py 4-CF3 100 na 





















































5 Py RF 5 Py RF 
a 3-Py 2-F g 4-Py 2-F 
b 3-Py 3-F h 4-Py 3-F 
c 3-Py 4-F i 4-Py 4-F 
d 3-Py 2-CF3 j 4-Py 2-CF3 
e 3-Py 3-CF3 k 4-Py 3-CF3 
f 3-Py 4-CF3 l 4-Py 4-CF3 
 






































Scheme 2. Tautomeric forms of fluorinated 7-aryl-2-pyridyl-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-amines (5a-l).  
Scheme legends  
 




Scheme 2. Tautomeric forms of fluorinated 7-aryl-2-pyridyl-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-amines (5a-l).  
 
